Cyteir Therapeutics Stock EBITDA
Cyteir Therapeutics' fundamental analysis aims to assess its intrinsic value by examining key economic and financial indicators - such as cash flow records, changes in balance sheet accounts, income statement trends, financial ratios, and relevant microeconomic factors affecting Cyteir Stock price.
Cyteir |
Cyteir Therapeutics Company EBITDA Analysis
Cyteir Therapeutics' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Cyteir Therapeutics EBITDA | (33.41 M) |
Most of Cyteir Therapeutics' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cyteir Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
CompetitionAccording to the company disclosure, Cyteir Therapeutics reported earnings before interest,tax, depreciation and amortization of (33.41 Million). This is 103.81% lower than that of the Biotechnology sector and 133.36% lower than that of the Health Care industry. The ebitda for all United States stocks is 100.86% higher than that of the company.
Cyteir EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cyteir Therapeutics' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cyteir Therapeutics could also be used in its relative valuation, which is a method of valuing Cyteir Therapeutics by comparing valuation metrics of similar companies.Cyteir Therapeutics is currently under evaluation in ebitda category among its peers.
Cyteir Fundamentals
| Return On Equity | -0.24 | |||
| Return On Asset | -0.14 | |||
| Current Valuation | (20.89 M) | |||
| Shares Outstanding | 36 M | |||
| Shares Owned By Insiders | 6.63 % | |||
| Shares Owned By Institutions | 76.83 % | |||
| Number Of Shares Shorted | 319.73 K | |||
| Price To Earning | 0.36 X | |||
| Price To Book | 0.87 X | |||
| Gross Profit | (16.59 M) | |||
| EBITDA | (33.41 M) | |||
| Net Income | (33.22 M) | |||
| Cash And Equivalents | 166.4 M | |||
| Cash Per Share | 4.71 X | |||
| Total Debt | 889 K | |||
| Debt To Equity | 0.02 % | |||
| Current Ratio | 19.95 X | |||
| Book Value Per Share | 3.47 X | |||
| Cash Flow From Operations | (25.79 M) | |||
| Short Ratio | 3.07 X | |||
| Earnings Per Share | (0.93) X | |||
| Price To Earnings To Growth | (0.03) X | |||
| Target Price | 3.0 | |||
| Number Of Employees | 46 | |||
| Beta | 0.096 | |||
| Market Capitalization | 108.71 M | |||
| Total Asset | 153.23 M | |||
| Retained Earnings | (138.11 M) | |||
| Working Capital | 143.89 M | |||
| Current Asset | 834.8 M | |||
| Current Liabilities | 366.9 M | |||
| Net Asset | 153.23 M |
Thematic Opportunities
Explore Investment Opportunities
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Other Consideration for investing in Cyteir Stock
If you are still planning to invest in Cyteir Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Cyteir Therapeutics' history and understand the potential risks before investing.
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings |